Can a new biologic drug prevent COPD Flare-Ups?
NCT ID NCT07725939
First seen Jul 24, 2026 · Last updated Jul 24, 2026
Summary
This phase 2 trial tests whether galvokimig, an experimental biologic drug, can reduce the number of moderate-to-severe COPD flare-ups in people with chronic bronchitis. About 400 adults aged 40 to 80 with moderate-to-severe COPD will receive either galvokimig or a placebo as an injection over 24 to 52 weeks. The main goal is to see if the drug delays the first serious flare-up compared to placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- an experimental biologic drug called galvokimig
- What this could lead to
- If it works, galvokimig could offer a new way to prevent COPD flare-ups and slow lung decline in people with chronic bronchitis.
- What could go wrong
- This is an early phase 2 trial, so the drug may not prove effective or safe. Side effects from a biologic are possible, and results may not apply to all COPD patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH CHRONIC BRONCHITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••